Jpmorgan Chase & CO Belite Bio, Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Belite Bio, Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 14,636 shares of BLTE stock, worth $893,674. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,636
Previous 6,356
130.27%
Holding current value
$893,674
Previous $297,000
210.77%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BLTE
# of Institutions
22Shares Held
280KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$10.3 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.22 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.12 Million0.0% of portfolio
-
Ubs Group Ag12.2KShares$745,3590.0% of portfolio
-
Morgan Stanley New York, NY10.6KShares$648,3350.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.52B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...